R & D Direction

Slow controlled release technology is a new type of preparation with very high technical content in modified release preparations. With the purpose of improving the quality of life (QOL) of patients, it can improve the disadvantages such as poor stability of drugs, difficulty in delivery and frequent use of drugs, improve the therapeutic effect of drugs and give full play to the best clinical efficacy of drugs.

In foreign countries, most controlled release preparations have been separated from the preliminary research stage and formed a highly industrialized scale. Currently, there are more than 1400 sustained-release pharmaceutical products in the global market, and 75% of the new drugs approved by FDA in the United States are new or improved preparations of existing drugs. Slow and controlled release preparations occupy the second place in the drug release system market, with the sales volume of about 36.1 billion us dollars in 2009, and it is expected to reach 45.8 billion us dollars in 2014, with the compound growth rate of 4.9%. Many well-known drug companies have benefited, such as seroquel, astrazeneca's blockbuster treatment for schizophrenia, whose sales of sustained-release tablets exceeded $1 billion for four consecutive years at the end of 2013.

Nanjing zeheng pharmaceutical technology development co., ltd. focuses on the development of drug slow-release technology, and has developed and applied a number of drugs with slow-release technology.